Anticancer Treatments and Cardiotoxicity

Mechanisms, Diagnostic and Therapeutic Interventions

Inbunden, Engelska, 2016

Av Patrizio Lancellotti, Jose L Zamorano, Maurizio Galderisi, Belgium) Lancellotti, Patrizio (Professor of Cardiology, University of Liege, Liege, Spain) Zamorano, Jose L, MD, FESC (Professor and Head of Cardiology, University Hospital Ramon y Cajal, Madrid, Italy) Galderisi, Maurizio (Associate Professor of Cardiology, Clinical Director, Federico II University Hospital, Jose L. Zamorano

1 679 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.

This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.

Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients
Written by world-leading experts in the field of cardiotoxicity
Includes high-quality images, case studies, and test questions
Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment

Produktinformation

Utgivningsdatum2016-12-09
Mått152 x 229 x 29 mm
Vikt910 g
FormatInbunden
SpråkEngelska
Antal sidor470
FörlagElsevier Science
ISBN9780128025093

Tillhör följande kategorier

Onkologi inom Medicin

Patricio Lancellotti is head of the intensive care cardiology unit at the University of Liège Hospital Center and Professor of Clinical Medicine at the University of Liège. His research, conducted at Professor Luc Piérard's department of cardiology, has led to significant progress in the care of patients suffering from functional mitral insufficiency, a pathology often underestimated clinically yet weighing heavily on the prognosis. He has 300 peer-reviewed articles and an H-index = 40. José Luis Zamorano is Professor of Medicine and Head of Cardiology at the University Complutense in Madrid and Director of the Cardiovascular Institute at the University Clinic San Carlos, Madrid. His key research interests include ischemic heart disease, cardiovascular risk factors and imaging modalities. Professor Zamorano is President Elect of the European Association of Echocardiography (EAE) and President of the Working Group on Non-invasive Diagnostic Imaging of the Spanish Society of Cardiology. He serves on numerous Editorial Boards, including the European Journal of Echocardiography, the American Society of Echocardiography and the European Heart Journal. He has authored over 400 articles for peer-reviewed journals and has an H-index = 57. Maurizio Galderisi, is Associate Professor of Cardiology and Clinical Director at Federico II University Hospital in Italy. His research interests include cardiac function, heart failure, arterial hypertension, tissue Doppler and strain rate imaging, coronary flow reserve. He has served as editor of one book and author of 10 chapters in various cardiologic books. He is the author or co-author of 250 articles on international peer-reviewed indexed journals, with an H-index = 38. He has been an invited speaker at more than 70 major national and international meetings and holds scientific association membership with Società Italiana di Cardiologia (SIC), Società Italiana di Ecografia Cardiovascolare (SIEC), European Association of Echocardiography (EAE), and the American Society of Echocardiography (ASE).

Section I: General Considerations1. Epidemiology and Trend of Prognosis in Cancer Patients2. Categories of Anticancer Treatments3. Classification by Mechanisms of Cardiotoxicity4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?5. The Impact of RadiotherapySection II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart6. Lessons From Preclinical Models7. Genetic and Epigenetic Risk Factors8. Changes of Myocardial Structure and Function9. Alteration of Heart Valves10. Pericardial Damage11. Effects of Radiotherapy on Vessels and Coronary Arteries12. Cardiac Conduction DisturbancesSection III: Cardiovascular Complications of Cancer Treatments13. Cardiac Rhythm Disturbances14. Acute and Chronic Heart Failure15. Coronary Artery Disease16. Pericardial Effusion and Pericarditis17. Radiation-Induced Carotid Atherosclerosis18. Valvular Heart Disease19. Atrial Fibrillation and Stroke in Cancer PatientsSection IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients20. The Role of Echocardiography21. The Role of Cardiovascular Magnetic Resonance (CMR)22. Nuclear Medicine Imaging and CardiotoxicitySection V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers25. Screening and Comprehensive Follow-Up Evaluation26. Preoperative Assessment for Noncardiac SurgerySection VI: Cardiotoxicity in Childhood27. Cardiotoxicity of Childhood Cancer TreatmentsSection VII: Management of Anticancer Drugs Related Cardiotoxicity28. Nonpharmacologic Therapy29. Beta-Blockers30. Angiotensin-Converting Enzyme Inhibition31. Diuretics32. Antiarrhythmic Drugs33. Anticoagulation in Cancer Patients34. New Drugs: The Beneficial Effects of Ranolazine35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients36. Focus on the Patient With Known Cardiac Disease37. Multidisciplinary Approach to Cardiac Disease in Cancer PatientsSection VIII: Future Research Priorities38. Pharmacogenomics Screening39. Cardiac Monitoring During Clinical Trials40. Preventive Therapy41. Cardiotoxicity: Future Research Directions